Cogent Biosciences, Inc.

Cogent Biosciences, Inc.

COGTNYSE / NASDAQHealthcareSmall cap

$26.72-$1.02 (-3.7%)

Last close · Data as of Nov 20, 2026

Market cap
$5.6B
P/E
-17.0x
EV / EBITDA
-17.2x
Revenue
$0.00
ROCE
-38.2%

-23.0% over the last year

Cogent Biosciences, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-14.5%
3M
-24.3%
6M
-18.9%
1Y
-23.0%
5Y
Hidden
  • This period includes a one-day price step on 10 Nov 2025 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change -$1.02 (-3.7%) from $28 to $27 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in COGT, bought on each weekday since 2021.

News & filings

What Cogent Biosciences filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 329 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are more than ten times current liabilities.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases.

Read moreShow less

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.

Sector
Healthcare
Shares outstanding
161.0M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$5.6B
P/E
-17.0x
P/B
10.2x
EV / EBITDA
-17.2x
52-week high
$42.84
52-week low
$26.72

Profitability

ROE
-60.1%
ROCE
-38.2%
ROIC
-45.7%
ROA
-35.1%

Growth

Revenue
$0.00
Net profit growth, 1Y
28.6%
Free cash flow
-$266.0M

Solvency

Current ratio
14.23
Debt / Equity
0.44
Debt / Assets
0.25
CFO / Net profit
0.80
Cash / Market cap
5.6%

Revenue and net profit

Annual revenue, with net profit as the dashed line.

Cogent Biosciences, Inc. revenue and net profit by fiscal year
Cogent Biosciences, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$140.2M
FY2023$0.00-$192.4M
FY2024$0.00-$255.9M
FY2025$0.00-$328.9M

Cash flows

FY2025: -$264.4M from operations, -$266.0M free after investment (dashed).

Cogent Biosciences, Inc. operating and free cash flow by fiscal year
Cogent Biosciences, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$118.6M-$125.5M
FY2023-$153.6M-$156.4M
FY2024-$207.8M-$208.4M
FY2025-$264.4M-$266.0M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00
EBITDA
-$321.3M
Net profit
-$328.9M
Cash from operations
-$264.4M
Free cash flow
-$266.0M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$321.3M-$328.9M-$266.0M-60.1%—+28.6%

Monthly returns

Month-by-month returns of COGT across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$937.6M
Liabilities$301.2M
Equity$636.4M
Paid-in capital$1.7B
Retained earnings-$1.2B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; COGT highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

Not shown (no positive earnings and no EV / Sales): Cogent Biosciences, Inc., Terns Pharmaceuticals, Inc., CRISPR Therapeutics AG, Scholar Rock Holding Corporation.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Cogent Biosciences, Inc.COGTthis company$5.6B-17.0x10.2x-60.1%-17.2x
Terns Pharmaceuticals, Inc.TERN$6.1B-63.6x6.1x-9.6%-51.0x
Rhythm Pharmaceuticals, Inc.RYTM$6.0B—22.3x-74.8%—
PACS Group, Inc.PACS$5.9B31.0x6.3x20.2%25.0x
Mirum Pharmaceuticals, Inc.MIRM$5.6B-241.4x17.9x-7.4%329.1x
Liquidia CorporationLQDA$5.6B-80.7x124.3x-154.0%-128.8x
CRISPR Therapeutics AGCRSP$5.5B—2.9x-30.3%—
Scholar Rock Holding CorporationSRRK$5.4B—22.1x-154.0%—
Xenon Pharmaceuticals Inc.XENE$5.1B-14.8x8.8x-59.5%-13.3x
Peer median—-63.6x13.4x-44.9%-13.3x

Year-to-date ROI

COGT since 1 January, against earlier years.

Historical volatility

COGT's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

LineFY2025
Operating expensesOperating Expense$333.4M
Research and developmentResearch And Development$269.8M
Total expensesTotal Expenses$333.4M
Pretax incomePretax Income-$328.9M

Learn while you research

Academy chapters picked for Cogent Biosciences, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →